XR-4 can selectively promote wild-type p53 accumulation in cancer cells, and then activate the downstream target genes, p21 and PUMA, of the p53 pathway to inhibit cancer cell proliferation and induce cell apoptosis. The gene discussed is BBC3; the disease is cancer.